Table 1.
Patient’s characteristics during follow up
| Clinical presentation | Fractures | T-score lumbar/total hip BMD (SD) | Calcaemia (mmol/l) | Treatments | |
|---|---|---|---|---|---|
| Follow up of the patient (January 2005) | Bicycle fall | L2 | −3.2/−2.1 | 2.50 | Initiation: denosumab (60 mg semi-annually), calcium (1 g daily), vitamin D (800 IU daily) |
| FREEDOM 3-year evaluation (January 2008) | No pain | T5, T8, and aggravation of L2 | −2.2/−1.7 | 2.52 | Pursuit: denosumab (60 mg semi-annually), calcium (1 g daily), vitamin D (800 IU daily) |
| FREEDOM extension (September 2013) | No pain | No new fracture | −1.6/−1.1 | 2.73 | All treatments stopped |
| Hospitalization (June 2014) | Acute intense dorsal pain | T4, T9, T10, T11, L1, L3 | −2.0/−1.3 | 2.83 | None |
| New evaluation (September 2016) | Chronic dorsal and lumbar pain | No new fracture | −2.9/−2.3 | 2.47 | Zoledronate (two infusions of 5 mg annually), vitamin D (100,000 IU quarterly) |
| New evaluation (August 2018) | Chronic lumbar pain | No new fracture | −2.9/−2.3 | 2.60 | Treatments stopped |
BMD bone mineral density, L1 first lumbar vertebra, L2 second lumbar vertebra, L3 third lumbar vertebra, SD standard deviation, T4 fourth thoracic vertebra, T5 fifth thoracic vertebra, T8 eighth thoracic vertebra, T9 ninth thoracic vertebra, T10 tenth thoracic vertebra, T11 11th thoracic vertebra